Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 451-471 , June 2006

Ankylosing spondylitis and bowel disease

  • Dominique Baeten, MD, PhD (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Division of Clinical Immunology and Rheumatology, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

References 

  1. Wright V. Seronegative polyarthritis: a unified concept. Arthritis and Rheumatism. 1978;21:619–633
  2. Dougados M, van der Linden S, Juhlin R, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis and Rheumatism. 1991;34:1218–1227
  3. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Revue du Rhumatisme et des Maladies Osteo-Articulaires. 1990;57:85–89
  4. Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Annals of the Rheumatic Diseases. 2002;61(supplement 3):iii1–iii8
  5. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheumatic Diseases Clinics of North America. 1998;24:785–813
  6. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheumatic Diseases Clinics of North America. 1998;24:737–751
  7. Moller P, Vinje O, Kass E, Berg K. The distribution of clinical findings in Bechterew's syndrome (ankylosing spondylitis) suggests distinct genetic subgroups. Clinical Genetics. 1982;22:151–159
  8. Purrmann J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. The Journal of Rheumatology. 1988;15:1658–1661
  9. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of Rheumatology. 2000;27:2860–2865
  10. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. The Journal of Rheumatology. 2001;28:2667–2673
  11. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis and Rheumatism. 1994;37:23–31
  12. Mielants H, Veys EM, Cuvelier C, De Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. British Journal of Rheumatology. 1988;27:S95–S105
  13. Mielants H, Veys EM, De Vos M, et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. The Journal of Rheumatology. 1995;22:2266–2272
  14. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. The Journal of Rheumatology. 1995;22:2273–2278
  15. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. The Journal of Rheumatology. 1995;22:2279–2284
  16. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis and Rheumatism. 2001;44:2728–2736
  17. Martinez-Gonzalez O, Cantero-Hinojosa J, Paule-Sastre P, et al. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. British Journal of Rheumatology. 1994;33:644–647
  18. Vaile JH, Meddings JB, Yacyshyn BR, et al. Bowel permeability and CD45RO expression on circulating CD20+B cells in patients with ankylosing spondylitis and their relatives. The Journal of Rheumatology. 1999;26:128–135
  19. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391
  20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism. 1984;27:361–368
  21. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of Rheumatology. 2002;29:511–515
  22. Peeters H, Van der Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Annals of the Rheumatic Diseases. 2004;63:1131–1134
  23. Podswiadek M, Punzi L, Stramare R, et al. The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo. 2004;56:110–113
  24. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. The Journal of Rheumatology. 2003;30:518–522
  25. Queiro R, Maiz O, Intxausti J, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clinical Rheumatology. 2000;19:445–449
  26. Colbert RA. The immunobiology of HLA-B27: variations on a theme. Current Molecular Medicine. 2004;4:21–30
  27. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis and Rheumatism. 1997;40:1823–1828
  28. Sims AM, Wordsworth BP, Brown MA. Genetic susceptibility to ankylosing spondylitis. Current Molecular Medicine. 2004;4:13–20
  29. Enlow RW, Bias WB, Arnett FC. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis and Rheumatism. 1980;23:1359–1365
  30. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603
  31. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis and Rheumatism. 2002;46:1629–1633
  32. Miceli-Richard C, Zouali H, Lesage S, et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis and Rheumatism. 2002;46:1405–1406
  33. D'Amato M. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. The Journal of Rheumatology. 2002;29:2470–2471
  34. van der Paardt M, Crusius JB, de Koning MH, et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes and Immunity. 2003;4:77–78
  35. Ferreiros-Vidal I, Amarelo J, Barros F, et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. The Journal of Rheumatology. 2003;30:102–104
  36. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Annals of the Rheumatic Diseases. 2005;64:930–935
  37. Bjarnason I, Helgason KO, Geirsson AJ, et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology. 2003;125:1598–1605
  38. Mielants H, Veys EM, Cuvelier C, et al. Gut inflammation in children with late onset pauci-articular juvenile chronic arthritis and evolution to adult spondyloarthropathy: a prospective study. The Journal of Rheumatology. 1993;20:1567–1572
  39. Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. The Journal of Rheumatology. 1995;22:680–683
  40. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut. 1987;28:394–401
  41. Demetter P, Van Huysse JA, De Keyser F, et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. The Journal of Pathology. 2002;198:517–522
  42. De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110:1696–1703
  43. Demetter P, De Vos M, Van Damme N, et al. Focal upregulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated lineage. American Journal of Clinical Pathology. 2000;114:364–370
  44. Demetter P, Baeten D, De Keyser F, et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Annals of the Rheumatic Diseases. 2000;59:211–216
  45. Elewaut D, De Keyser F, Cuvelier C, et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scandinavian Journal of Gastroenterology. 1998;33:743–748
  46. Elewaut D, De Keyser F, Van den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. The Journal of Rheumatology. 1998;25:1932–1937
  47. Van Damme N, Elewaut D, Baeten D, et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clinical and Experimental Rheumatology. 2001;19:681–687
  48. Van Damme N, De Keyser F, Demetter P, et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clinical and Experimental Immunology. 2001;125:383–390
  49. Van Damme N, De Vos M, Baeten D, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Annals of the Rheumatic Diseases. 2001;60:495–499
  50. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163. Annals of the Rheumatic Diseases. 2005;64:321–324
  51. Ogura Y, Bonen DK, Inohara NR, et al. frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606
  52. Hoffman IE, Demetter P, Peeters M, et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Annals of the Rheumatic Diseases. 2003;62:455–459
  53. Torok HP, Glas J, Gruber R, et al. Inflammatory bowel disease-specific autoantibodies in HLA-associated spondyloarthropathies: increased prevalence of AS pANCA. Digestion. 2004;70:49–54
  54. Vander Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clinical and Experimental Immunology. 2005;140:354–359
  55. Severijnen AJ, Hazenberg MP, Van De Merwe JP. Induction of chronic arthritis in rats by cell wall fragments of anaerobic coccoid rods isolated from the faecal flora of patients with Crohn's disease. Digestion. 1988;39:118–125
  56. Severijnen AJ, Van Kleef R, Hazenberg P, Van de Merwe JP. Cell wall fragments from major residents of the human intestinal flora induce chronic arthritis in rats. The Journal of Rheumatology. 1989;16:1061–1068
  57. Mansson I, Norberg R, Olhagen B, Bjorklund NE. Arthritis in pigs induced by dietary factor: microbiological, clinical and histological studies. Clinical and Experimental Immunology. 1971;9:677–693
  58. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63:109–112
  59. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine. 1994;180:2359–2364
  60. Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. Journal of Immunology. 1996;156:794–803
  61. May E, Dorris ML, Satumtira N, et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis and colitis in HLA-B27 transgenic rats. Journal of Immunology. 2003;170:1099–1105
  62. Tran TM, Satumtira N, Dorris ML, et al. HLA-B27 in transgenic rats form disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. Journal of Immunology. 2004;172:5110–5119
  63. Cuvelier CA, De Wever N, Mielants H, et al. Expression of T cell receptors alpha beta and gamma delta in the ileal mucosa of patients with Crohn's disease and with spondyloarthropathy. Clinical and Experimental Immunology. 1992;90:275–279
  64. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Annals of the Rheumatic Diseases. 2000;59:945–953
  65. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of the entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases. 2001;60:316–321
  66. Mertz AK, Wu P, Sturniolo T, et al. Multispecific CD4+T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. Journal of Immunology. 2000;164:1529–1537
  67. Kuon W, Holzhutter HG, Appel H, et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated disease. Journal of Immunology. 2001;167:4738–4746
  68. Thiel A, Wu P, Lauster R, et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis and Rheumatism. 2000;43:2834–2842
  69. Goodall JC, Beacock-Sharp H, Deane KH, Gaston JS. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4+T cells from humans infected with Chlamydia trachomatis. Clinical and Experimental Immunology. 2001;126:488–493
  70. Duchmann R, Lambert C, May E, et al. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clinical and Experimental Immunology. 2001;123:315–322
  71. Salmi M, Jalkanen S. Human leucocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. Journal of Immunology. 2001;166:4650–4657
  72. Baeten D, Kruithof E, Van den Bosch E, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis and Rheumatism. 2001;44:186–195
  73. Yin Z, Braun J, Neure L, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis and Rheumatism. 1997;40:1788–1797
  74. Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Annals of the Rheumatic Diseases. 2001;60:36–42
  75. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases. 2001;60:750–755
  76. Yin Z, Siegert S, Neure L, et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology. 1999;38:1058–1067
  77. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases. 2000;59:263–268
  78. Braun J, Yin Z, Spiller I, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis and Rheumatism. 1999;42:2039–2044
  79. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. The Journal of Pathology. 2002;196:343–350
  80. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research & Therapy. 2005;7:R359–R369
  81. Baeten D, Moller HJ, Delanghe J, et al. Association of CD163 positive macrophages and local production of CD163 with decreased lymphocyte activation in spondyloarthropathy synovitis. Arthritis and Rheumatism. 2004;50:1611–1623
  82. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection and Immunity. 2000;68:7010–7017
  83. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis and Rheumatism. 2005;52:2146–2158
  84. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism. 1995;38:499–505
  85. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis and Rheumatism. 2000;43:1244–1256
  86. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205
  87. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases. 2006;65(4):442–452
  88. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgraduate Medical Journal. 1981;57:297–299
  89. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. The American Journal of Gastroenterology. 2000;95:1949–1954
  90. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Annals of Internal Medicine. 1987;107:513–516
  91. Cipolla G, Crema F, Sacco S, et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacological Research. 2002;46:1–6
  92. Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619–622
  93. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. The American Journal of Gastroenterology. 2000;95:1946–1948
  94. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2004;10:751–757
  95. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments for ankylosing spondylitis. Annals of the Rheumatic Diseases. 2002;61(supplement 3):iii40–iii50
  96. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Annals of the Rheumatic Diseases. 2005;64:124–126
  97. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases. 2005;64:296–298
  98. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis and Rheumatism. 2002;46:755–765
  99. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–1193
  100. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. The New England Journal of Medicine. 2002;346:1349–1356
  101. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford, England). 2005;44:342–348
  102. Braun J, Sieper J. Biological therapies in the spondyloarthritides—the current state. Rheumatology (Oxford, England). 2004;43:1072–1084
  103. van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism. 2005;52:582–591
  104. Rudwaleit M, Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy. 2005;5:1095–1109
  105. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis—clinical and MRI results of a 52-week open-label trial. Arthritis and Rheumatism; 2006; 54: 678–681.
  106. van der Heijde D, Kivitz A, et al. Adalimumab therapy results in significant reductions of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial. Arthritis and Rheumatism. 2005;52(supplement 1):S281
  107. Braun J, Davis J, Dougados M, et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2006;65(3):316–320
  108. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821–1822
  109. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Annals of the Rheumatic Diseases. 2004;63:1664–1669
  110. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Annals of the Rheumatic Diseases. 2003;62:74–76
  111. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. The American Journal of Gastroenterology. 2002;97:2688–2690
  112. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I study group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549
  113. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine. 2005;353:2462–2476
  114. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811
  115. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. The American Journal of Gastroenterology. 2001;96:2564–2568
  116. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094
  117. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis and Rheumatism. 2005;53:856–863
  118. Davis JC, Van Der Heijde D, Braun J, et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and Rheumatism. 2003;48:3230–3236
  119. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. The Journal of Rheumatology. 2005;32:752–753
  120. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Annals of the Rheumatic Diseases. 2005;64:1305–1310
  121. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774–1785
  122. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut. 2004;53:70–77
  123. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. The American Journal of Gastroenterology. 2004;99:1984–1989
  124. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. The American Journal of Gastroenterology. 2005;100:75–79

PII: S1521-6942(06)00040-4

doi: 10.1016/j.berh.2006.03.010

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 451-471 , June 2006

Article Tools

* Image Usage & Resolution